Such comparator datasets will also provide information on the impact of novel targeted therapies (BRAF and MEK inhibitors) on similar tumour control, neuroendocrine, and neurobehavioural outcomes in this vulnerable group and require intensive collaborative efforts. The gene discussed is MAP2K7; the disease is neoplasm.